BridgeBio Pharma, Inc. (BBIO) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Biotechnologie Branche. Der Hauptsitz des Unternehmens ist in Palo Alto, CA, United States. Der aktuelle CEO ist Eric Michael David.
BBIO hat IPO-Datum 2019-06-27, 725 Vollzeitbeschäftigte, gelistet an der NASDAQ Global Select, eine Marktkapitalisierung von $15.06B.
BridgeBio Pharma, Inc. is a biopharmaceutical company focused on discovering, developing, and delivering medicines for genetic diseases. The company maintains a pipeline of 30 development programs spanning early-stage discovery through late-stage clinical development, including product candidates such as AG10 for TTR amyloidosis-cardiomyopathy, BBP-831 for pediatric achondroplasia, BBP-631 for congenital adrenal hyperplasia, and Encaleret for autosomal dominant hypocalcemia. BridgeBio's therapeutic focus extends across rare genetic disorders, oncology, and gene therapy, supported by collaboration agreements with leading academic institutions including Stanford University and the University of California. Founded in 2015 and headquartered in Palo Alto, California, the company leverages both small molecule and gene therapy approaches to address unmet medical needs in Mendelian and genetic disease markets.
